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Background: Citizens, patients and their representatives are increasingly insisting on working with health
professionals to organize and discuss research protocols. The International Committee of Medical Journal Editors
recommended setting up a public clinical trial registry where anyone can find key information about a trial. Around
the world, governments have, in fact, now begun to legislate mandatory disclosure of all clinical trials. The aims of
the present survey were to assess the availability of clinical trial registries for Italian citizens and to examine the
transparency of the data items reported.
Methods: The availability of open-access clinical trial registries was surveyed on a sample of 182 websites, including
research institutes and centers of excellence (IRCCS-teaching hospitals), hospitals and associations. For each registry
we downloaded a sample of two trials to assess the correspondence of the data items reported. Results from the
Italian and international registries were compared.
Results: Fifteen percent of the sample had an open-access registry of clinical trials. Comparison of the data items
available, in terms of completeness and transparency, from institutional and international registries indicated wide
variability.
Conclusions: Italian citizens, patients and their associations have scant access to local registries of clinical trials, and
international registries are generally more informative. On the European level, advocacy and lobby actions are
needed among citizens and patients to boost the diffusion of open-access clinical trial registries without language
barriers, thereby facilitating participation, access to information, and the coordination of clinical research.
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Demand from citizens, patients and their representatives
for information about clinical trials (CT) has been grow-
ing for many years [1,2]. Laypeople are increasingly
aware of the need to participate in health decisions and
want a more active role rather than just that of a passive
subject in a CT [3,4]. Published personal and collective
experiences very clearly report that patients’ needs are
unmet in the research agenda [5-7]. These unmet needs
are related to several aspects such as the choice of pri-
mary endpoints for CT relevant for patients, the increase
in independent head-to-head comparison studies of dif-
ferent pharmacological or assistance strategies, the ac-
cess to easy-to-understand lay-language information* Correspondence: mosconi@marionegri.it
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distribution, and reproduction in any mediumabout on-going CT, the rapid publication of all results
whether positive or negative, and, last but not least, a re-
search agenda designed according to the priorities dis-
cussed by all the stakeholders, including citizen and
patients or their representatives.
A recent review states that making the patient more
aware makes a CT more acceptable and increases the
number of subjects recruited, but the persisting lack of
information does not help patients decide whether and
how to participate in clinical research [8]. Citizens’ and
patients’ organizations are seeking to set up working
groups with clinical researchers through training pro-
grams [9], discussion of research protocols [10,11], or in-
formation projects. Investigators are being urged to
spread more information on ongoing CT and results [4].
Currently in industrialized countries approval to start
a CT must be obtained from ethics committees, andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pants. According to the Declaration of Helsinki, patients
who take part in a CT must be adequately informed on
the aims, methods, expected benefits and potential risks
of participation, and the latest version specifies that be-
fore recruitment of the first subject every CT must be
registered in an open-access registry [12].
Despite a moral obligation to report the positive or
negative results of any research on humans, some spon-
sors keep quiet about negative findings when publishing
their data, or when submitting them to regulatory au-
thorities [13]. This also happens with CTs involving par-
ticipants in low- and middle-income countries with
inadequate oversight mechanisms [14].
The International Committee of Medical Journal Edi-
tors (ICMJE) has promoted the establishment of a public
clinical trials registry (CTR) [15]. Its purpose would be
to promote access to information so everyone can find
key information about CTs, and also to help shape med-
ical decision-making. Since that decision, many govern-
ments have made disclosure of all CTs mandatory [16].
Since 2004 the transparency of CTs involving children in
four European countries (France, Italy, United Kingdom
and Spain) has been guaranteed by the DEC-net registry
(Drug Evaluation in Children - the European registry of
CTs on medicines for children). In 2004 DEC-net was
one of only three international records compliant with
the ICMJE and World Health Organization (WHO)
rules. DEC-net’s work monitoring ongoing studies means
it can potentially help avoid trial duplication and facili-
tate better distribution of funds based on the unmet
therapeutic needs of children [17].
Since March 2011, after years of use restricted to na-
tional authorities, all European citizens able to read
English have had free access to information on drug
CTs approved in Europe, thanks to the new registry
created by the European Medicines Agency (EMA)
[18]. The registry was assembled after extensive con-
sultations with all those concerned, such as patients
and health professionals, to ensure that their needs
were taken into account during its design [19].
In Italy, the national registry on CTs of medicines
has been active since 2000, developed by the Italian
Medicines Agency (AIFA), a national public body re-
sponsible for drug regulation operating under the dir-
ection of the Ministry of Health, with access limited
to health professionals. In 2005, this registry of CTs
on drug comparison was made accessible to citizens
as well.
To evaluate the availability of open-access CTRs for
citizens and patients and to evaluate the transparency of
the data items in comparison with international regis-
tries, we carried out this survey in several hospitals, re-
search centers and association websites.Methods
We visited a sample of 182 official Italian websites be-
tween March 7 and April 20 2011:
 All IRCCS-teaching hospitals, that is, 42 research
institutes and centers of excellence,
 A convenience sample of public hospitals involved in
CT multicenter projects: CERP (collaborative group
for cancer pain, n=59), MANGO and MITO
(collaborative groups for ovarian cancer, n=65)
[20,21],
 A convenience sample of 16 national associations1
or federations of patients involved in the Mario
Negri Institute PartecipaSalute project [22].
We checked all the websites for open-access CTR, or
for a section on CTs in progress, or at least for a link to
other registries.
Data items collected
For each CTR identified we recorded whether the fol-
lowing data items were collected: unique trial number,
title, pathology, presence or absence of treatment, type
or phase of the study, approval by the ethics committee,
sponsor, aim, inclusion and exclusion criteria, primary
and secondary outcomes, starting date, number of
patients needed, recruiting status, contact persons, lan-
guage of the registry, presence of a glossary, updating of
the website/registry, considering December 2010 as clos-
ing date, and any publication or references related to the
CTs. These are recognized as the 20 minimum items to
be collected in a registry, as required by the World
Health Organization [23].
For each Italian CTR found we checked the presence
or absence of the data items, and to verify how the data
items list corresponded two CTs were randomly down-
loaded and printed. Similarly, two CTs were downloaded
from CTRs of the 11 international institutions2 from the
International Clinical Trials Registry Platform (ICTRP)
database [24], and of AIFA, where only drug CTs are
reported. Descriptive statistics, mainly proportions, were
used to analyze all data collected.
Results
Out of 182 Italian health institution websites visited, 15
(8%) had CTR for consultation by citizens, nine in the
north of Italy, five in the center and one national associ-
ation (Table 1). None of those without a CTR, had a link
to another registry or the AIFA or European registry.
One IRCCS-teaching hospital mentioned that it was
possible to participate in the trial after an appointment
with an oncologist.
We compared the availability of data items on the CTs
reported in Italian CTRs with international registries
Table 1 Registries of clinical trials in the institutions
surveyed
Number YES (%) NO (%)
IRCCS-teaching hospitals 42 11 (26) 31 (74)
Hospitals 124 3 (2) 121 (98)
Associations 16 1 (6) 15 (94)
TOTAL 182 15 (8) 167 (92)
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has all data items reported in each CT’s record.
Generally, the registries almost always collected the title
and pathology in the database (80-93%), the trial phase,
sponsors and contacts (67%), type of treatment (60%) and
aim of the trial (47%). Important data items such as inclu-
sion and exclusion criteria or starting date were reported
in only 7% of the Italian registries. All these percentages
were higher in the international registries, many of them
institutional. A glossary was very rare.
Because of the small number of CTR, it was impos-
sible to compare IRCCS-teaching hospitals and public


























*Related to the CTs.Discussion
The internet is a very important tool for retrieving health
information [25], and increasing numbers of citizens use
the web as an easy way to find information. Italian citizens
and patients, however, have scant access to clinical infor-
mation about CTs. The institutional AIFA registry, where
only drug CTs are reported, is an open-access resource,
but because it is not linked to hospitals or associations,
patients and citizens are not aware of the existence of this
useful information. In addition, the data items collected by
the 15 Italian CTRs in our sample are not satisfactory, and
are poor compared to international or AIFA CTRs. The
ICMJE recommends a minimum set of data items for
CTR [16]; our sample had from 7% to 93%. Considering
the increasing interest of citizens and patients in partici-
pating in the debate on health and clinical research [5-7],
it is important to have information on CTs that is easily
accessible enabling people to ask for admission to a trial
(for example, inclusion/exclusion criteria, telephone con-
tact). It is also important to use non-technical language or
at least to provide a glossary. The language used by Italian
CTRs is mostly technical, and in only one case was ‘lay’
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IRCCS-teaching hospitals, but only a convenience sam-
ple of associations or federations and public hospitals.
However, all the hospitals were involved in CTs, and
the associations/federations cover representative path-
ologies like cancer, cardiovascular disease and neuro-
logical disorders. Second, the international comparison
only looked at the 11 registries set up by international
institutions. Finally, the data refer only to the Italian sce-
nario but demand for open-access, user-friendly,
complete CTRs is worldwide [26-29], and this is an im-
portant challenge to facilitate the access to and participa-
tion in CTs.
Conclusions
Non-English speaking European citizens or patients,
such as Italians, face a significant language barrier in
consulting international databases in English. However,
the importance of access to information on CTs is inter-
nationally recognized, as recently discussed in India [27],
Germany [28,29], and Australia [26].
Our results suggest that advocacy and lobby actions at
local and international levels are needed among clini-
cians, researchers, and citizens or patients, and their
organizations, to boost sensitivity to this issue and to
clinical research in general (‘you get better care where
they do research’) [4]. It is important to demand that
every hospital, clinical research center, or patients’
organization, set up their own CTRs on their own web-
sites [30] and - even more importantly – to create links
to institutional open-access CTRs, like the available
drug-oriented CTRs.
The EMA should continue to work with stakeholders
to improve the EU Clinical Trials Registry, improving
the quality and completeness of data and ease of con-
sultation. EMA could have a strong driving effect, pub-
lishing a higher-quality registry, and promoting
initiatives for all European countries.
Endnotes
1List of associations (focus of the association’s activ-
ities is in brackets): AIRC (cancer); TELETHON (neuro-
logical disorders); AI (Alzheimer); AICE (epilepsy);
AIMA (Alzheimer); AISM (multiple sclerosis); ANLAIDS
(AIDS); CO.NA.CUORE (cardiovascular diseases);
EUROPA DONNA (breast cancer); EUROPA UOMO
(prostate cancer); AIMAC or FAVO (cancer); LILA
(AIDS); FEDERASMA (asthma); FISH (handicap); AISLA
(amyotrophic lateral sclerosis); FAND (diabetes).
2List of International registry: CLINICALTRIALS.
GOV; ANZCTR (Australian New Zealand Clinical Trials
Registry); WHO (World Health Organization); ISRCTN
REGISTER; CHICTR (Chinese Clinical Trial Registry);
DRKS (Deutsches Register Klinischer Studien); CTRI(Clinical Trials Registry- India); IRCT (Iranian Registry
of Clinical Trials); NTR (Netherlands Trial Register);
SLCTR (Sri Lanka Clinical Trial Registry); EU.
CLINICALTRIALSREGISTER.
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